Big Pharmacy Opens New Marketing Mode of O2O Internet
Release time:
2020-12-01
Big Pharmacy Opens O2O Internet New Marketing Model
On November 20, Jianfeng Big Pharmacy launched the Meituan and Hungry Noodles online sales platform and officially joined the O2O Internet marketing camp.
Prior to this, the third-party Jiugongge order processing platform organized an online launch meeting to clarify the contents of the first launch time, the number of first-time online stores, the situation of unlaunched stores, the configuration of relevant network equipment in stores, commodity price information, docking personnel, training of Jiugongge order processing platform and order testing, etc. respectively, requiring large pharmacies to organize stores to participate in DingTalk live broadcast training, emphasize the importance of pre-launch training. At present, the first batch of 11 companies on-line direct management stores, covering Jinhua Wucheng, development, Jindong three districts. In mid-December, 19 independent accounting stores and franchise stores will be launched, covering Jinhua, Yongkang and Lanxi. On-line varieties of positioning over-the-counter drugs, class I and class II medical devices, Chinese medicine tablets, health food, consumer products, and the use of the platform's Internet hospital resources, one after another on-line prescription drugs.
major pharmacy online stores take advantage of the high popularity of Meituan and Hungry Noodles on the mobile payment side, and take advantage of online preferential promotion activities on various platforms, such as "first order reduction", "full reduction" and "old friend subsidy" to receive orders. As of November 28, the first batch of online stores have reached a total of 198 transactions on the two platforms of Meituan and Hungry Noodles.
According to the feedback from the store's online one week, in order to standardize the online sales behavior of pharmacies, all departments of major pharmacies will continue to do a good job in regional drug pricing and drug information verification, online sales information filing and supervision, platform sales reconciliation, platform installation and maintenance, and standardization of online and offline sales.
Next, the big pharmacy will also coordinate and communicate with Jinhua Medical Insurance Bureau and Ali Health, and launch the "National Medical Insurance Electronic Voucher" scan code payment module when hungry, so that the insured can use the mobile phone Alipay end to choose the module to pay when placing an order on the platform. The big pharmacy Yishou Shenhang Pharmacy will also become the first pilot pharmacy in Jinhua City to have the payment function of medical insurance electronic certificate on the Hungry Noodles platform. (Lang Minxiao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page